Dogwood Therapeutics, Inc. Proceeds from Notes Payable
Dogwood Therapeutics, Inc. (DWTX) had Proceeds from Notes Payable of $3.00 million as of 2025-02-18, per its 10-Q filed 2025-11-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2025-11-07
- 2025-02-18: Proceeds from Notes Payable $3.00M.
- 2024-10-07: Proceeds from Notes Payable $16.50M.
| Period end | Proceeds from Notes Payable |
|---|---|
| 2025-02-18 | $3.00M 10-Q · filed 2025-11-07 |
| 2024-10-07 | $16.50M 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |